Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Gene therapy of inherited and acquired hearing loss

Project description

Treating hearing loss via gene therapy approaches

Millions of people worldwide suffer from hearing loss due to ageing, congenital causes or prolonged exposure to loud noises. The EU-funded iHEAR project is working towards a gene therapy approach to treat hearing loss. The project involves the investigation of the best vector to transfer therapeutic genes into the cells responsible for sensorial neural hearing loss, the inner ear hair cells and spiral ganglion neurons. Researchers will use cells from patients suffering from hearing loss as a model for testing the gene therapy and gene editing strategies. Collectively, the iHEAR project will advance current tools for studying and treating hearing loss.

Objective

To address the substantial financial and social burden caused by hearing loss in 360 million people world-wide, I aim to improve hearing via gene therapy to correct inherited and protect from acquired hearing loss. In vitro experiments will establish the best vector configurations for transfer of therapeutic genes and miRNAs into inner ear hair cells (HC) and spiral ganglion neurons (SGN). The efficiency of the best-performing vector designs will then be explored in vivo using fluorescent marker proteins. Cell-type specific and inducible promoters as well as receptor-targeted vectors will be employed as a safety measure and to ensure transgene expression in HC and SGN target cells. Once efficient transduction of appropriate target cells and proper expression of therapeutic proteins are demonstrated, I will perform proof-of-concept studies in hearing loss models, incl. established mouse models, to correct (WP1) or protect (WP2) from impaired hearing. To ensure translatability of these findings, I will generate human induced pluripotent stem cells (iPSC) from patients with hearing loss (WP3), so that I can test optimized constructs in human otic cells. Moreover, I have access to a collection of well-characterized samples from over 600 hearing loss patients, including children with congenital hearing loss in whom many novel monogenetic alterations were identified. These resources provide the unique opportunity to generate a novel toolbox for the treatment of hearing loss. In addition to lentiviral and adeno-associated viral (AAV) vector delivery of corrective or protective genes to treat hearing loss, I will apply state-of-the-art genome editing tools to model and correct mutations causative for hearing loss in cell lines, primary cells from murine models, human patients and patient-derived iPSC. This work will contribute to development of clinically translatable approaches for precision medicine strategies to improve hearing loss treatment.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

ERC-COG - Consolidator Grant

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2018-COG

See all projects funded under this call

Host institution

HANNOVER CLINICAL TRIAL CENTER GMBH
Net EU contribution
€ 1 999 500,00
Address
CARL NEUBERG STR 1 K 27 OE 9751
30625 Hannover
Germany
Region
Niedersachsen Hannover Region Hannover
Activity type
Research Organisations
Links
Total cost
€ 1 999 500,00

Beneficiaries (1)